Literature DB >> 659922

Immunization with a human diploid cell strain of rabies virus vaccine: two-year results.

K G Nicholson, G S Turner, F Y Aoki.   

Abstract

Antibody responses following primary vaccination with 1.0 ml of intramuscularly (im) or 0.1 ml of intradermally (id) administered human diploid cell rabies virus vaccine were observered for two years. Three primary doses of vaccine were given to 77 volunteers on days 0, 28, and 56. An antibody response was detected in all vacinees after a single dose; at one month, the response in the group that received vaccine id was identical to that in the group that was given vaccine im, although only 1/10th of the dose of vaccine was used. After the second and third doses, the antibody responses were higher with the primary im regimen; this difference was significant at two, three, and 12 months when the geometric mean titers of antibody were twofold higher for im than for id vaccination. The antibody responses to a booster dose of vaccine administered to randomly grouped volunteers by the subcutaneous or id route at six, 12, or 24 months were similar irrespective of the method of primary immunization but were greater with increasing intervals between primary and booster doses.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 659922     DOI: 10.1093/infdis/137.6.783

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose.

Authors:  Xiaowei Zhang; Zhenggang Zhu; Chuanlin Wang
Journal:  Clin Vaccine Immunol       Date:  2011-07-13

2.  Persistence of rabies antibody 5 years after pre-exposure prophylaxis with human diploid cell antirabies vaccine and antibody response to a single booster dose.

Authors:  F M Rodrigues; V B Mandke; M Roumiantzeff; C V Rao; J M Mehta; K M Pavri; C Poonawalla
Journal:  Epidemiol Infect       Date:  1987-08       Impact factor: 2.451

3.  Human diploid-cell-culture vaccine for rabies prophylaxis.

Authors:  F Y Aoki
Journal:  Can Med Assoc J       Date:  1979-05-05       Impact factor: 8.262

4.  Evaluation of a human diploid cell strain rabies vaccine: final report of a three year study of pre-exposure immunization.

Authors:  G S Turner; K G Nicholson; D A Tyrrell; F Y Aoki
Journal:  J Hyg (Lond)       Date:  1982-08

5.  Multisite intradermal antirabies vaccination. Immune responses in man and protection of rabbits against death from street virus by postexposure administration of human diploid-cell-strain rabies vaccine.

Authors:  K G Nicholson; H Prestage; P J Cole; G S Turner; S P Bauer
Journal:  Lancet       Date:  1981-10-24       Impact factor: 79.321

6.  Intradermal immunization with human diploid cell rabies vaccine: serological and clinical responses of immunized persons to intradermal booster vaccination.

Authors:  M J Burridge; J W Sumner; G M Baer
Journal:  Am J Public Health       Date:  1984-05       Impact factor: 9.308

7.  Intradermal vaccination against hepatitis B virus infection in an endemic area (Nigeria), two year results.

Authors:  E A Ayoola; M A Atoba; A O Johnson
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

8.  Immunogenicity and feasibility of intradermal vaccination against rabies in Quebec.

Authors:  Y Bui; M Sow; E Cambron-Goulet; E Levac; F Milord
Journal:  Can Commun Dis Rep       Date:  2015-03-05

9.  Enzyme-linked immunosorbent assay: a rapid reproducible test for the measurement of rabies antibody.

Authors:  K G Nicholson; H Prestage
Journal:  J Med Virol       Date:  1982       Impact factor: 2.327

Review 10.  Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis.

Authors:  Jenny L Schnyder; Cornelis A De Pijper; Hannah M Garcia Garrido; Joost G Daams; Abraham Goorhuis; Cornelis Stijnis; Frieder Schaumburg; Martin P Grobusch
Journal:  Travel Med Infect Dis       Date:  2020-09-06       Impact factor: 6.211

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.